1,000 Shares in BioLife Solutions, Inc. (NASDAQ:BLFS) Bought by Steward Partners Investment Advisory LLC

Steward Partners Investment Advisory LLC acquired a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 1,000 shares of the medical equipment provider’s stock, valued at approximately $26,000.

Other large investors have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $28,000. Quest Partners LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $57,000. Smartleaf Asset Management LLC boosted its holdings in shares of BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after buying an additional 950 shares during the period. Intech Investment Management LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth $255,000. Finally, Stifel Financial Corp boosted its holdings in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares during the period. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Trading Up 0.6 %

Shares of BLFS stock opened at $25.48 on Thursday. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -24.04 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a fifty day moving average of $26.48 and a 200-day moving average of $25.49.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. During the same quarter in the prior year, the company posted ($0.21) EPS. On average, equities research analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the subject of several recent analyst reports. Benchmark reaffirmed a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. StockNews.com raised shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright increased their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Finally, KeyCorp increased their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

Insider Buying and Selling

In related news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the completion of the sale, the chief financial officer now owns 121,779 shares in the company, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Todd Berard sold 1,577 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $39,425.00. Following the sale, the chief marketing officer now owns 104,961 shares of the company’s stock, valued at $2,624,025. This trade represents a 1.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,117 shares of company stock worth $534,442 in the last quarter. 2.20% of the stock is owned by corporate insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.